Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Pharmacogenomic Regulation: Three Guidances, Fall Workshop

Executive Summary

FDA is planning to issue three guidances on pharmaco-genomics over the next 18 months

You may also be interested in...



FDA Genomics Guidance Paves Way For PKG Firms; Genaissance May Benefit

Genaissance Pharmaceuticals is developing a pharmacogenomics-based assay for predicting an individual occurrence of agranulocytosis associated with the antipsychotic clozapine (Novartis' Clozaril and generics)

FDA Genomics Guidance Paves Way For PKG Firms; Genaissance May Benefit

Genaissance Pharmaceuticals is developing a pharmacogenomics-based assay for predicting an individual occurrence of agranulocytosis associated with the antipsychotic clozapine (Novartis' Clozaril and generics)

Pharmacogenomics Moves Into Spotlight With Completion Of Genome Project

Industry is ready to "embrace" pharmacogenomic-based drug development as long as commercial and regulatory applications are based on a full understanding of the technology, AstraZeneca VP-Clinical Development Glenn Gormley, MD/PhD, said during FDA's risk management public workshop April 9

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel